Opinion: Cardiologist Questions if New Cholesterol Drug Enlicitide is a True Game-Changer

Cardiologist Vishal Khetpal expresses cautious skepticism about enlicitide (Lipfendra), a newly approved cholesterol medication, questioning whether it will significantly change clinical prescribing patterns. While the drug represents an advance in cholesterol management, experts suggest immediate adoption may not be widespread among practitioners. The opinion highlights the importance of evaluating new medications beyond their novelty, considering real-world effectiveness, safety profiles, and practical applicability for patients with high cholesterol and heart disease risk.

Originally published on
STAT News
By Vishal Khetpal
Read full article(opens in new tab)Fetched: July 22, 2026 at 10:02 AM



